MCP Server For Financial Data by EODHD Learn more

Celldex Therapeutics Inc icon

Celldex Therapeutics Inc (CLDX NASDAQ) stock market data APIs

$29.9923 0.66(2.2%)
as of March 12, 2026
Try our APIs with free plan!

Celldex Therapeutics Inc Financial Data Overview

Price chart is built with Anychart

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.

Prev. Close 29.9923
Open 30.6479
High 30.6971
Low 29.1087
52 wk Range 14.4-31.99
Market Cap 1 989 M
Shares Outstanding 66 566 K
Revenue 1 545 K
EPS -1.22
Beta 1.256

* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.


ETFs with Celldex Therapeutics Inc (top by weight)

Ticker
100-day Price Change
Weight
SURI.US Simplify Propel Opportunities ETF
0.06 (0.34%)
3.44
SBIO.US ALPS Medical Breakthroughs ETF
0.67 (1.35%)
1.33
BBC.US Virtus LifeSci Biotech Clinical Trials ETF
4.68 (12.74%)
0.84
IWN.US iShares Russell 2000 Value ETF
4.63 (2.54%)
0.14
VRTVX.US Vanguard Scottsdale Funds - Vanguard Russell 2000 Value ETF
8.12 (2.56%)
0.11
VTWV.US Vanguard Russell 2000 Value Index Fund ETF Shares
3.87 (2.4%)
0.11
ESML.US iShares ESG Aware MSCI USA Small-Cap ETF
0.68 (1.48%)
0.07
IWM.US iShares Russell 2000 ETF
-1.39 (-0.56%)
0.07
SXRG.F iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc EUR
17.2 (3.42%)
0.06
VRTIX.US Vanguard Russell 2000 Index Fund Institutional Shares
-2.23 (-0.58%)
0.05

* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.


Why to choose EODHD?

Prices start at $19.99

24/7 Live support

Robust, powerful and reliable data

API Simplicity of a few lines of code


Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW

Get Celldex Therapeutics Inc data using free add-ons & libraries


Get Celldex Therapeutics Inc Fundamental Data

Celldex Therapeutics Inc logo

Celldex Therapeutics Inc Fundamental data includes:

  • Net Revenue: 1 545 K
  • EBITDA: -283 987 008
  • Earnings Per Share:
  • Income Statements
  • Balance Sheets
  • Cash flows

Plans with Fundamental data

Starting from

$ 59.99 /mo.
COMPARE PLANS

End-of-day & Earnings data

Get Celldex Therapeutics Inc Earnings data

Calendar & News package for

$ 19.99 /mo.

What’s included:

  • Latest Release: 2026-03-02
  • EPS/Forecast: -1
GET THE PACKAGE

Get Celldex Therapeutics Inc End-of-day data

EOD Historical Data package for

$ 19.99 /mo.

What’s included:

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
GET THE PACKAGE

Celldex Therapeutics Inc News

Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026 New

Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026

- Late breaking Poster Presentation at AAAAI - - Ability to retreat facilitates a real-world paradigm in which treatment for ColdU and SD may be intermittent with barzolvolimab - HAMPTON, N.J., Marc...

Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026

Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026

Celldex Therapeutics, Inc. - Late breaking Poster Presentation at AAAAI - - Ability to retreat facilitates a real-world paradigm in which treatment for ColdU and SD may be intermittent with barzolvo...

Celldex Therapeutics, Inc. (CLDX): A Bull Case Theory

Celldex Therapeutics, Inc. (CLDX): A Bull Case Theory

We came across a bullish thesis on Celldex Therapeutics, Inc. on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on CLDX. Celldex Therapeutics, Inc.'s share was trading a...

Is Celldex Therapeutics (CLDX) Pricing Reflecting Recent 46% One-Year Surge And DCF Upside Potential

Is Celldex Therapeutics (CLDX) Pricing Reflecting Recent 46% One-Year Surge And DCF Upside Potential

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. If you are wondering whether Celldex Therapeutics at around...

Get Celldex Therapeutics Inc fresh news feed via Financial News API

Calendar & News package for

$19.99/mo.

Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW
  • Flexibility: No long-term commitments, just a minimum of one month
  • Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.

What’s included:

  • API Calls per Day: 100 000/day
  • API Requests per Min.: 1000/minute
  • Type of Usage: Personal use

Data access:

Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.

GET THE PACKAGE
Chat

Send the request

Leave your email and our team will contact you ASAP.